Mesoblast (NASDAQ:MESO) Sees Strong Trading Volume – What’s Next?

Mesoblast Limited (NASDAQ:MESO) shares saw an uptick in trading volume on Thursday . 1,283,734 shares were traded during mid-day trading, an increase of 78% from the previous session’s volume of 722,881 shares.The stock last traded at $15.00 and had previously closed at $12.25.

Wall Street Analysts Forecast Growth

MESO has been the subject of several recent research reports. Jefferies Financial Group raised Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research note on Thursday, August 29th. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, September 24th. Finally, StockNews.com downgraded shares of Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Mesoblast Trading Up 35.4 %

The business has a fifty day moving average of $10.24 and a two-hundred day moving average of $8.17. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Signaturefd LLC lifted its holdings in shares of Mesoblast by 128.7% during the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after buying an additional 3,099 shares in the last quarter. Pine Valley Investments Ltd Liability Co bought a new stake in shares of Mesoblast during the 2nd quarter worth $80,000. Perkins Coie Trust Co grew its holdings in shares of Mesoblast by 15.0% during the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after purchasing an additional 1,500 shares during the last quarter. Rathbones Group PLC bought a new stake in shares of Mesoblast during the second quarter worth $95,000. Finally, XTX Topco Ltd acquired a new position in Mesoblast in the 2nd quarter worth about $103,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.